Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Honda, Hirokazu ^a   Kobayashi, Yasuna ^a   Onuma, Shoko ^a   Shibagaki, Keigo ^b   Yuza, Toshitaka ^b   Hirao, Keiichi ^b   Yamamoto, Toshinori ^a   Tomosugi, Naohisa ^c   Shibata, Takanori ^a  

^a SHOWA UNIVERSITY   (Japan)

^b Shibagaki Dialysis Clinic   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BIOLOGICAL MARKER; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROFERRONE; FERRIC OXIDE; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; ERFE PROTEIN, HUMAN; ERYTHROPOIETIN; HEPCIDIN 25, HUMAN; MACROGOL; PEPTIDE HORMONE; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ERYTHROPOIESIS; FEMALE; HEMODIALYSIS; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; VENOUS BLOOD; BIOSYNTHESIS; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PROSPECTIVE STUDY; RETICULOCYTE COUNT; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; BIOMARKERS; CROSS-SECTIONAL STUDIES; DARBEPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HEPCIDINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEPTIDE HORMONES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECEPTORS, TRANSFERRIN; RENAL DIALYSIS; RETICULOCYTE COUNT; TIME FACTORS; TRANSFERRIN;

EID: 84961614136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151601     Document Type: Article

References (16)

1. Lankhorst CE, Wish JB Anemia in renal disease: diagnosis and management. Blood Rev. 2010; 24: 39-47 doi: 10.1016/j.blre.2009.09.001 PMID: 19833421
2. Zumbrennen-Bullough K., Babitt JL The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant. 2014; 29: 263-273 doi: 10.1093/ndt/gft443 PMID: 24235084
3. Shoji S, Inaba M, Tomosugi N., Okuno S, Ichii M, Yamakawa T., et al. Greater potency of darbepoietin-a than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol 2013; 90: 237-244 doi: 10.1111/ejh.12067 PMID: 23281632
4. Kakimoto-Shino, Toya Y, Kuji T, Fujikawa T, Umemura S. Changes in Hepcidinand Reticulocyte Hemoglobin Equivalent Levels in Response to Continuous Erythropoietin Receptor Activator Administration in Hemodialysis Patients: A Randomized Study. Ther Apher Dial. 2014; 18: 421-426 doi: 10.1111/1744-9987.12161 PMID: 24456328
5. Morikami Y, Fujimori A, Okada S., Kumei M, Mizobuchi N, Sakai M. Comparison of 2-Week versus 4-Week Dosing Intervals of Epoetin Beta Pegol on Erythropoiesis and Iron Metabolism in Hemodialysis Patients. Ther Apher Dial. 2014; 18: 414-420 doi: 10.1111/1744-9987.12164 PMID: 24456373
6. Onuma S, Honda H, Kobayashi Y., Yamamoto T, Michihata T, Shibagaki K., et al. Effects of long-term erythropoiesis-stimulating agents on iron metabolism in patients on hemodialysis. Ther Apher Dial. 2015; 19: 582-589. doi: 10.1111/1744-9987.12322 PMID: 26481900
7. Kautz L, Jung G, Valore E.V., Rivella S., Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46: 678-684. doi: 10.1038/ng.2996 PMID: 24880340
8. Kauts L, Nemeth E. Molecular liaisons between erythropoiesis and iron metabolism. Blood. 2014; 124: 479-482 doi: 10.1182/blood-2014-05-516252 PMID: 24876565
9. Ciniselli CM, De Bortoli M, Taverna E, Varinelli L., Pizzamiglio S, Veneroni S, et al Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone. Expert Rev Proteomics: 2015; 12: 695-701 doi: 10.1586/14789450.2015.1099436 PMID: 26496240
10. Tsubakihara Y, Nishi S, Akiba T., Hirakata H, Iseki K, Kubota M., et al. 2008 Japanese Society for Dialysis Therapy: guideline for renal anemia in chronic kidney disease. Ther Apher Dial 2010; 14: 240-275 doi: 10.1111/j.1744-9987.2010.00836.x PMID: 20609178
11. Tomosugi N, Kawabata H, Wakatabe R., Higuchi M, Yamaya H, Umehara H., et al. Detection of serum hepcidin in renal failure and inflammation by using Protein Chip System. Blood. 2006; 108: 1381-1387 PMID: 16621968
12. Kuragano T, Shimonaka Y, Kida A., Furuta M, Nanami M, Otaki Y., et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010; 31: 534-540. doi: 10.1159/000312381 PMID: 20484891
13. Tessitore N, Girelli D, Campostrini N., Bedogna V, Pietro Solero G, Castagna A, et al Hepcidin is not useful as a biomarkerfor iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2010; 25: 3996-4002 doi: 10.1093/ndt/gfq321 PMID: 20538788
14. van derWeerd N.C., Grooteman MP, Bots M.L., van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One. 2012; 7: e39783. doi: 10.1371/journal.pone.0039783 PMID: 22808058
15. Seldin MM, Peterson JM, Byerly M.S., Wei Z., Wong GW. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem 2012; 287: 11968-11980 doi: 10.1074/jbc.M111.336834 PMID: 22351773
16. van derWeerd N.C., Grooteman MP, Bots M.L., van den Dorpel MA, den Hoedt CH, Mazairac AH, et al; CONTRAST Investigators. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013; 28: 3062-3071 doi: 10.1093/ndt/gfs488 PMID: 23147161